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Bioactive Lipids and Cationic Antimicrobial Peptides as New
Potential Regulators for Trafficking of Bone Marrow-Derived
Stem Cells in Patients with Acute Myocardial Infarction
Anush V. Karapetyan,1,2,* Yuri M. Klyachkin,1,2,* Samy Selim,1,2 Manjula Sunkara,1,2 Khaled M. Ziada,1,2
Donald A. Cohen,3 Ewa K. Zuba-Surma,4,5 Janina Ratajczak,4 Susan S. Smyth,1,2 Mariusz Z. Ratajczak,4,6
Andrew J. Morris,1,2 and Ahmed Abdel-Latif1–3
Acute myocardial infarction (AMI) triggers mobilization of stem cells from bone marrow (BM) into peripheral
blood (PB). Based on our observation that the bioactive sphingophospholipids, sphingosine-1 phosphate (S1P),
and ceramide-1 phosphate (C1P) regulate trafficking of hematopoietic stem cells (HSCs), we explored whether
they also direct trafficking of non-hematopoietic stem cells (non-HSCs). We detected a 3–6-fold increase in
circulating CD34 + , CD133 + , and CXCR4 + lineage-negative (Lin - )/CD45 - cells that are enriched in non-
HSCs [including endothelial progenitors (EPCs) and very small embryonic-like stem cells (VSELs)] in PB from
AMI patients (P < 0.05 vs. controls). Concurrently, we measured a *3-fold increase in S1P and C1P levels in
plasma from AMI patients. At the same time, plasma obtained at hospital admission and 6 h after AMI strongly
chemoattracted human BM-derived CD34 + /Lin - and CXCR4 + /Lin - cells in Transwell chemotaxis assays.
This effect of plasma was blunted after depletion of S1P level by charcoal stripping and was further inhibited by
the specific S1P1 receptor antagonist such as W146 and VPC23019. We also noted that the expression of S1P
receptor 1 (S1P1), which is dominant in naı̈ve BM, is reduced after the exposure to S1P at concentrations similar
to the plasma S1P levels in patients with AMI, thus influencing the role of S1P in homing to the injured
myocardium. Therefore, we examined mechanisms, other than bioactive lipids, that may contribute to the
homing of BM non-HSCs to the infarcted myocardium. Hypoxic cardiac tissue increases the expression of
cathelicidin and b-2 defensin, which could explain why PB cells isolated from patients with AMI migrated more
efficiently to a low, yet physiological, gradient of stromal-derived factor-1 in Transwell migration assays. To-
gether, these observations suggest that while elevated S1P and C1P levels early in the course of AMI may trigger
mobilization of non-HSCs into PB, cathelicidin and b-2 defensin could play an important role in their homing to
damaged myocardium.
Introduction
Acute myocardial infarction (AMI) leads to ischemicheart disease (IHD) and is one of the most prevalent
causes of death and morbidity in the United States and
worldwide [1–3]. Despite significant advances in medical
therapy and interventional strategies, the prognosis of milli-
ons of patients with AMI and IHD remains dismal [4,5].
Currently, there are no therapies that can replace the infarcted
myocardium, and therapies are mostly symptomatic. The
shortage of donor hearts available for transplantation creates
a need to develop new myocardial regenerative strategies,
including stem cell therapies.
Cardiomyocytes undergo continuous renewal, maintained
at least in part by bone marrow (BM)-derived cells [6–8]. We
focused our studies on non-hematopoietic stem cells (non-
HSCs) that include populations such as CD34 + , CD133 + ,
and CXCR4 + lineage-negative (Lin - )/CD45 - cells, as they
are enriched in very small embryonic-like stem cells (VSELs)
[9–11]. While the mechanisms of cardiomyocyte renewal are
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poorly understood, this process is capable of renewing up to
half of the cardiomyocytes during the normal life span [12].
In rodents, this phenomenon is dynamic, responds to myo-
cardial injury [13], and is maintained, at least in part, by
BM-derived cells [14]. AMI initiates innate reparatory
mechanisms through which non-HSCs are mobilized from
BM into peripheral blood (PB) and chemoattracted to the
ischemic myocardium, a process that can potentially con-
tribute to myocardial regeneration as we and others have
demonstrated [15–20]. Nevertheless, very little is known
about the underlying mechanism and clinical significance of
this mobilization phenomenon. Clinical studies investigating
stem cell mobilization as a strategy to augment repair of the
infarcted myocardium have achieved limited success, prob-
ably as result of the low number of mobilized non-HSCs
homing to damaged heart tissue [21–24].
Similarly, the process of recruitment of stem cells from BM
into PB itself is still not fully understood. The a-chemokine
stromal derived factor-1 (SDF-1) has been identified as a
potent stem cell chemoattractant present in PB plasma [25].
Recently, however, other factors, notably bioactive lipids—
sphingosine-1 phosphate (S1P) and ceramide-1 phosphate
(C1P), have been identified in PB as major HSCs chemoat-
tractants that enhance their egress from BM into PB [26–29].
SDF-1 has been also reported to become u-pregulated in
hypoxia inducible factor-1a (HIF-1a) manner at sites of organ
tissue injury (eg, in infarcted myocardium) [30–32]. While a
role for the SDF-1/CXCR4 axis in stem cell trafficking is
undisputed, its exclusive role in homing to a highly proteo-
lytic microenvironment, such as the ischemic/infarcted
myocardium, is less established, and redundant mechanisms
may exist [27,33,34]. The limited contribution of SDF-1 to
myocardial regeneration may be explained by its active
degradation at the sites of inflammation and myocardial
infarction by metalloproteinases [33,35,36]. However, as re-
cently demonstrated, despite SDF-1 degradation by prote-
ases, the chemotactic responsiveness of HSCs to even low
SDF-1 gradient could be significantly enhanced by members
of the family of cationic antimicrobial peptides (CAMPs),
including products of complement cascade (CC) activation—
anaphylatoxin C3a [37–40] and fibroblast- and leukocyte-
derived-cathelicidin and b-2 defensin [41]. Thus, an increase
in the level of CAMPs at sites of injury enhances the re-
sponsiveness of stem cells to even very low levels of SDF-1.
Based on the above literature, we hypothesized and show
for the first time that bioactive lipids (S1P and C1P) and
elements of the innate immune system (cathelicidin and b-2
defensin) are up-regulated during AMI and can potentially
contribute to mobilization of non-HSCs from BM into PB
followed by their homing to the ischemic myocardium.
Materials and Methods
The study population consisted of 40 patients with acute
ST-elevation myocardial infarction (STEMI). We enrolled
30 age- and sex-matched subjects to the study population
into the control (CTRL) group. The CTRL group is asymp-
tomatic with no history of caronary artery disease but with a
similar risk factor profile to the STEMI group. Patients with
STEMI were referred within 12 h of symptom onset for pri-
mary percutaneous coronary intervention (PPCI). Patients
were excluded if they had a systemic inflammatory process,
cancer, recent motor vehicle accident, recent surgery, active
infection, history of MI or revascularization [coronary artery
bypass graft, percutaneous coronary intervention (PCI)],
unsuccessful revascularization, or onset of the symptoms
> 12 h. PB samples (3 mL of PB each) were obtained at pre-
sentation in all patients baseline denoting the time of arrival
to the hospital (BSL) followed by samples at 6, 12, 24, and 48
after PCI, and only PPCI patients were enrolled. BM samples
were obtained from normal individuals, and the BM cells
were examined by smear and flow cytometry for any path-
ological findings before being utilized in the chemotaxis ex-
periments. The study protocol complies with the Declaration
of Helsinki and was approved by the institutional ethics
committee. All patients provided written informed consent.
Quantitation of C1P and S1P
PB samples were obtained in ethylenediaminetetraacetic
acid tubes, and plasma was isolated by centrifuging whole
blood for 10 min at 800g. Supernatant was then removed and
centrifuged at 9,400g for 10 min to remove platelets, and the
supernatant was then used for lipid measurements. RBCs
were isolated using the leukocyte depletion kit (Pall, Inc.,
East hills, NY) and purified by centrifuging at 600g for
10 min followed by washing in normal saline at the same
speed. To asses the effect of activated complement on S1P
and C1P release, RBCs were incubated for 3 h at 37C with
saline, an antibody against RBCs alone (BD Biosciences, San
Jose, CA), normal human serum complement alone at a 1:5
dilution (Quidel, Santa Clara, CA), or antibody and com-
plement together. Lipids were extracted from plasma, su-
pernatant, and RBCs using acidified organic solvents, as
previously described [42]. An analysis of S1P and C1P was
carried out using a Shimadzu UFLC coupled with an AB
Sciex 4000-Qtrap hybrid linear ion trap triple quadrupole
mass spectrometer in multiple reaction monitoring mode as
previously described [43]. The mobile phase consisted of 75/
25 of methanol/water with formic acid (0.5%) and 5 mM
ammonium formate (0.1%) as solvent A and 99/1of metha-
nol/water with formic acid (0.5%) and 5 mM ammonium
formate (0.1%) as solvent B. For the analysis of various C1P
species, the separation was achieved by maintaining 75% of
solvent B for 3 min, then increasing to 100% B over the next
3 min, and maintaining at 100% B for the last 18 min. The
column was equilibrated back to the initial conditions in
3 min. The flow rate was 0.5 mL/min with a column tem-
perature of 60C. The sample injection volume was 10 mL.
The mass spectrometer was operated in the positive elec-
trospray ionization mode with optimal ion source settings
determined by synthetic standards with a declustering po-
tential of 46 V, entrance potential of 10 V, collision energy of
19 V, collision cell exit potential of 14 V, curtain gas of 30 psi,
ion spray voltage of 5,500 V, ion source gas1/gas2 of 40 psi,
and temperature of 550C.
Flow cytometric analysis and fluorescence-activated
cell sorting sorting of circulating primitive
stem cells from PB
Erythrocytes were lysed twice using BD Pharm Lyse lys-
ing buffer (BD Biosciences) at room temperature for 10 min
and subsequently washed in phosphate-buffered saline (PBS)
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to yield total nucleated cells (TNCs). TNCs were subse-
quently stained for hematopoietic lineages markers (Lin)
using the following fluorescein isothiocyanate-conjugated
antibodies (Abs) against humans: CD2 (clone RPA-2.10);
CD3 (clone UCHT1); CD14 (clone M5E2); CD16 (clone 3G8);
CD19 (clone HIB19); CD24 (clone ML5); CD56 (clone
NCAM16.2); CD66b (clone G10F5); and CD235a (clone GA-
R2). These Abs were purchased from BD Biosciences. The
cells were simultaneously stained for the panleukocytic
marker—CD45 (PE-Cy7conjugated Abs, clone HI30; BD
Biosciences) and one of the following antigens: CXCR4
(APC-conjugated Abs, clone 12G5; BD Biosciences), CD34
(APC-conjugated Abs, clone 581; BD Biosciences), CD133
(CD133/1, APC-conjugated Abs; Miltenyi Biotec, Auburn,
CA), S1P receptor-1 (PE-conjugated Abs, clone 218713; R&D
Systems, Minneapolis, MN), and S1P3 (primary antibody
followed by a secondary antibody labeled with PE-Cy7;
Santa Cruz Biotechnology, Santa Cruz, CA). Staining was
performed in PBS with 2% fetal bovine serum (FBS; In-
vitrogen, Carlsbad, CA) at 4C for 30 min. Cells were sub-
sequently washed, re-suspended, and analyzed using an LSR
II (BD Biosciences). At least 106 events were acquired from
each sample. The absolute numbers of circulating stem cells
were calculated (individually for each patient) per 1 mL of PB
based on the percentage content of these cells detected by
flow cytometry and the absolute number of white blood cells
per 1mL of PB. FlowJo software was used for the analysis
(Tree Star, Ashland, OR).
Chemotaxis assays
Cell migration assays were performed using the chemo-
tactic (Boyden) chamber (Neuroprobe, Gaithersburg, MD).
BM- and PB-derived cells were lysed as described earlier.
Cells were then suspended in S1P free medium (RPMI with
0.1% FBS) for 3 h before the migration assays. The lower
chambers were loaded with CTRLs or the testing agents. Cell
suspension (1 · 106 cells/100mL) was loaded into the upper
chambers on a 5mm membrane; the chambers were incubated
(37C, 95% humidity, and 5% CO2) for 3 h; and subsequently,
cells in the lower chambers were harvested, stained against
the lineage markers CD34 and CXCR4 as detailed earlier, and
counted by fluorescence-activated cell sorting. The lower
chambers contained no chemoattractant medium-Vehicle
(RPMI medium with 0.1% FBS, ie, CTRL) or plasma isolated
from STEMI patients during the peak mobilization of stem
cells. To examine the role of bioactive lipids in inducing BM-
derived stem cell migration, simultaneous experiments uti-
lizing charcoal-stripped plasma in the lower chamber were
performed. Similar to examining the role of S1P1 in this mo-
bilization, BM-derived cells were incubated with 10mM of the
selective S1P1 receptor antagonist W146 at 10mM (Cayman
Chemicals, Ann Arbor, MI) or VPC23019 at 10mM (Avanti
Polar Lipids, Alabaster, AL) for 1 h before the migration assay.
To examine the role of LL37 in PBCs migration, PB cells iso-
lated from patients with AMI (1 · 106 cells/100mL) were loa-
ded in the upper chambers. The lower chamber was loaded
with RPMI medium with 0.1% FBS alone or supplemented
with SDF-1 at 2 ng/mL (PeproTech, Rocky Hills, NJ) alone,
LL37 at 2.5 ng/mL (AnaSpec, Fremont, CA) alone, or the
combination of SDF-1 (2 ng/mL) and LL37 (2.5 ng/mL).
Chemotaxis in these experiments was conducted as detailed
earlier. All migration results are reported as fold migration
compared with CTRLs.
Myocardial ischemia and cardiac fibroblast
isolation experiments
Six C57/B6 mice were utilized in the myocardial hypoxia
experiments. Hearts were excised and canulated for the Lan-
gendorff apparatus, using perfusion buffer containing 4.7 mM
K+ and 1.8 mM Ca+ + . The CTRLs were allowed to beat for
50 min in warmed and oxygenated perfusion buffer and then
removed, and left ventricles were flash frozen in liquid nitro-
gen. The ischemic hearts were hung and allowed to beat for 5
or 6 min with flow in the warmed and oxygenated perfusion
buffer; then, the flow was stopped for 30 min, and the hearts
were bathed in the warmed buffer. After ischemia, flow was
restarted and the hearts started beating in about 0.5–1 min after
onset of flow and continued beating for 20 min to simulate
reperfusion injury. The left ventricles from ischemic hearts were
then flash frozen as detailed earlier. Frozen myocardial samples
were utilized for the real time-polymerase chain reaction
(RQ-PCR) experiments.
Cardiac fibroblasts were isolated from C57/B6 mice after
sacrificing mice and isolating the hearts. Left ventricular
tissues were minced into small pieces (less than 1 mm in
diameter) using razor blades. The minced left ventricular
tissues were incubated with HBSS solution (Invitrogen)
containing glucose, NaCl, KCl, and NaHCO3; and supple-
mented with diaspase and collagenase B (Roche, In-
diannapolis, IN) for 30 min followed by washing twice. Cell
pellets were incubated overnight in Dulbecco’s modified
Eagle medium (Invitrogen) supplemented with 10% FBS
(Thermoscientific, Waltham, MA) overnight. Floating cells
were washed, and adherent cells were allowed to grow to
70%–80% confluence. Hypoxia experiments were conducted
in hypoxia incubators, and cells were maintained at < 1% O2,
5% CO2, and 37C for either 2 h followed by 1 h reperfusion
or 72 h hypoxia followed by reperfusion. Cells were then
harvested and flash frozen for RQ-PCR.
Statistical analysis
Data are expressed as mean – standard error of the means.
Differences were analyzed using the unpaired Student t-test
or analysis of variance (one way or multiple comparisons) as
appropriate. Post hoc multiple comparison procedures were
performed using 2-sided Dunnett or Dunn tests as appro-
priate with CTRL samples as the CTRL category. The sig-
nificance level throughout the analyses was chosen to be
0.05. All statistical analyses were performed using the SPSS
(version 16) statistical software (SPSS, Inc., Chicago, IL). All
authors had full access to and took full responsibility for the
integrity of the data. All authors have read and agreed with
the article as written.
Results
Concurrent temporal elevation of plasma S1P and
C1P levels and non-HSCs numbers in PB after AMI
Our recent studies demonstrated the critical role of bio-
active lipids such as S1P ands C1P in the mobilization and
homing of BM-derived HSCs [27,28]. Since we expect that
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similar mechanisms are involved in the release of non-HSCs
from their BM niches in AMI, we examined the changes in
S1P levels in PB plasma after acute myocardial injury and as
compared with CTRLs. Figure 1 shows that, in comparison
to CTRLs, the levels of the bioactive lipid S1P were elevated
after AMI, particularly in the early phases after myocardial
ischemia and started decreasing after successful revascular-
ization. The level of S1P increased 3 fold to 0.31 – 0.02 mM as
compared with 0.14 – 0.02 in CTRLs (P < 0.01). S1P levels
then decreased after 6 h from the acute event but continued
to be elevated at 48 h compared with CTRLs (Fig. 1). In
whole blood, RBCs and platelets contain significantly higher
levels of S1P and C1P compared with plasma (Fig. 2A). Re-
lease of S1P and CIP from RBCs could, therefore, account for
higher plasma levels in the setting of AMI. Activation of CC
and the resultant generation of C5b-C9 (membrane attack
complex) may enhance release of S1P from RBCs. The CC
was activated in AMI patients [44–48], and in our AMI
population, C5b-C9 levels were elevated in serum (Supple-
mentary Fig. S1; Supplementary Data are available online at
www.liebertpub.com/scd). On incubation with activated CC
components, RBCs released S1P and C1P in a manner that
could account for the elevated plasma levels of S1P and C1P
in plasma of AMI patients (Fig. 2B, C). The higher plasma
levels at BSL may also reflect the release of C1P from dam-
aged cardiomyocytes as recently shown in the murine model
of acute heart ischemia [48]. However, the role of C1P in non-
HSC mobilization requires further studies, given the limited
and transient increase in its levels and somehow the lack of
temporal correlation with the number of mobilized non-
HSCs. It is important to mention that there are no recep-
tors identified for C1P, and, thus, receptor knockout or
receptor-blocking experiments are not possible at this time.
Nonetheless, our recent data in mice suggest an important
cooperative role of bioactive lipids in the egress from BM of
endothelial progenitor cells (EPCs), mesenchymal stem cells
(MSCs), and VSELs and the subsequent homing of these
circulating cells to the damaged heart tissue [26].
We observed a temporal correlation between the elevation in
plasma levels of bioactive lipids and the peak mobilization of
non-HSCs after acute myocardial injury (Fig. 3A–C). The ab-
solute numbers of non-HSCs populations such as Lin - /
CD45 - /CD34 + , Lin - /CD45 - /CXCR + , and Lin - /
CD45 - /CD133 + cells peaked at the early stages after myo-
cardial ischemia (4.8 – 1.3 vs. 0.7 – 0.04 cells/mL of PB, 8.6 – 2.5
vs. 0.7 – 0.06 cells/mL of PB, and 1.7 – 0.5 vs. 0.6 – 0.03 cells/mL
of PB 6 h after presentation in STEMI patients vs. CTRLs re-
spectively, P < 0.05). This mobilization correlated with the early
elevation of plasma levels of S1P and total C1P, thus suggesting
a chemotactic role for bioactive lipids.
BM-derived stem cells express S1P receptors
Given the potential role of bioactive lipids in the mobili-
zation of non-HSCs, we examined the expression of various
S1P receptors (S1Prs) on the surface of bone marrow stem
and progenitor cells (BMSPCs) isolated from normal indi-
viduals and found high expression of type 1 and type 3 S1P
receptors—S1Pr1 and S1Pr3 respectively (Fig. 4). These re-
ceptors play an important role in trafficking of lympho/
hematopoietic cells [49,50].
We focused on the subset of BM-derived cells Lin - /
CD34 + cells that are enriched in stem and progenitor cells,
and flow cytometry analysis revealed that Lin - /CD34 +
express both S1Pr1 (14.7% – 1.4%) and S1Pr3 (9.9% – 0.9%)
(Fig. 4). Furthermore and as described with lympho/hema-
topoietic cells [51,52], this expression was dynamic, and both
receptors were internalized in the presence of S1P (Fig. 4).
The expression of S1Prs on PB lineage-negative cells in the
early phases after AMI was significantly lower than in their
counterparts isolated from the BM (data not shown). The
increased level of plasma S1P could explain the possible in-
ternalization of S1Prs on circulating peripheral blood stem
and progenitor cells (PBSPCs). Of note, since C1P receptors
are not yet identified, we could not perform similar receptor
expression studies for this bioactive lipid.
BM-derived stem cells migrate toward plasma
isolated from acute myocardial ischemia patients
in an S1P-dependent manner
Since the plasma levels of S1P were elevated simulta-
neously with the peak mobilization of non-HSCs at 6 h after
revascularization, we sought to examine the role of bioactive
lipids in the migration of BMSPCs using in vitro migration
assays. Figure 5A and B shows that Lin - /CD34 + and
FIG. 1. Elevated levels of
bioactive lipids at early times
after AMI. Bar graphs show-
ing the plasma levels of
sphingosine-1 phosphate (A)
and ceramide-1 phosphate
(B) in patients with STEMI
and controls; showing peak
levels early in STEMI pa-
tients. (*P < 0.05 as compared
with controls). AMI, acute
myocardial infarction; BSL,
baseline denoting the time
of arrival to the hospital;
C1P, ceramide-1 phosphate;
S1P, sphingosine-1 phos-
phate; STEMI, ST-elevation
myocardial infarction.
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Lin - /CXCR4 + BMSCs migrate toward intact plasma iso-
lated from STEMI patients at the peak mobilization of non-
HSCs. This migration was inhibited by delipidation of the
plasma (charcoal stripping), which removed > 90% of the
S1P (Supplementary Fig. S2). In addition, pretreatment of
BM cells with the selective S1Pr1 antagonist, W146 (10 mM),
or the S1Pr1/S1Pr3 receptor antagonist, VPC23019 (10mM)
also significantly reduced the migration of BM cells toward
plasma from AMI patients. Neither W146 nor VC23019
altered cell viability (Supplementary Fig. S3). These data in
total support a potential role for bioactive lipids present in
the plasma of STEMI patients in the mobilization and
egress of stem cells from the BM to the PB. Our data
demonstrate multiple mechanisms responsible for stem cell
mobilization and homing in ischemic heart injury. For in-
stance, we noted increased expression of CXCR4 on mobi-
lized PB endothelial cells and cardiac fibroblasts under
hypoxic conditions that may facilitate these phenomena
(data not shown). Furthermore, exposure to S1P at 250 nM
increases the expression of CXCR4 on circulating mobilized
EPCs, which suggest an important interplay between bio-
active lipids and CXCR4 that can orchestrate stem cell
mobilization and homing in ischemic conditions as has been
recently shown [53].
FIG. 2. RBCs contain high concentrations of bioactive lipids that are released on complement activation. Bar graphs
showing the content of S1P in the plasma and purified RBCs (A). Content of S1P and C1P is significantly higher in the RBCs
compartment compared with plasma. On incubation with activated complement and activated complement together with
antibodies against RBCs, cells release both S1P (B) and C1P (C). (*P < 0.05 as compared with plasma or control). C1P,
ceramide-1 phosphate; RBCs, red blood cells; S1P, sphingosine-1 phosphate.
FIG. 3. Temporal increase in number of circulating BMSPCs at early times after AMI. Bar graphs showing the absolute
numbers of circulating non-hematopeitic stem cells (Lin - /CD45 - /CD34 + (A), CXCR4 + (B), and CD133 + (C)) enriched in
very small embryonic-like stem cells in the PB of AMI patients and controls; showing a peak mobilization early in STEMI
patients. (*P < 0.05 as compared with controls). PB, peripheral blood; BMSPCs, bone marrow stem and progenitor cells.
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Ischemic cardiac tissues express antimicrobial
cationic peptides cathelicidin and b-2 defensin
that enhance responsiveness of circulating
in PB cells to SDF-1 gradient
Our data highlighted the potential role of S1P and the
dynamic expression of its receptors in the chemotaxis of non-
HSCs from the BM to the PB in the setting of AMI (Figs. 1–5).
However, the reduced expression of S1Pr1 and S1Pr3 after
exposure to S1P levels similar to those encountered in the PB
(*250 mM) in the early phases after AMI (Fig. 4) suggest that
other mechanisms than those involving bioactive lipids may
be involved in their homing from PB to the myocardium. To
support this further, previous experiments have indicated
that S1P lyase activity is increased in the ischemic myocar-
dium, thus leading to S1P degradation, lower local levels of
S1P, and myocardial injury [54]. Therefore, it is unlikely that
S1P will play a major role in the homing of circulating non-
HSCs to myocardium.
Several reports suggest the involvement of the SDF-1 that
is up-regulated in HIF-1a manner in infarcted myocardium
in homing of stem cells to damaged heart tissues [55].
However, since infracted myocardium is enriched in pro-
teolytic enzymes [eg, metalloproteinases—matrix metallo-
proteinases (MMPs)] [56] that degrade SDF-1 [35,36], its
actual chemotactic gradient is usually low. As we have re-
cently demonstrated, despite SDF-1 degradation by MMPs,
the chemotactic responsiveness of stem cells to even low
SDF-1 gradient could be significantly enhanced by members
of the family of CAMPs, including products of CC activation–
anaphylatoxin C3a [57] and fibroblast- and leukocyte-derived
cathelicidin and b-2 defensin [41]. Given the above data, we
investigated the expression and potential role of CAMPs in
homing of non-HSCs into infracted myocardium.
Our assessment of the CC activation indicates that the
time course of this process correlated with our observation of
the peak elevation of S1P (Supplementary Fig. S1). Thus,
activation of CC may simultaneously release C3a in the
plasma that enhances responsiveness of BM cells to low SDF-
1 gradient. Next, we investigated whether the myocardium
expresses 2 other CAMPs (cathelicidin and b-2 defensin)
whose expression is regulated by hypoxia. To address this
question, we first employed the langendorff apparatus, and
murine cardiac ventricular tissues were subjected to ische-
mic/reperfusion injury (30 min ischemia followed by 20 min
reperfusion). Figure 6A shows increased expression of both
CAMPs in hypoxia/reperfusion as compared with CTRL
myocardium. We then examined cardiac fibroblasts sub-
jected to hypoxia using a hypoxic chamber, and the expres-
sion of cathelicidin and b-2 defensin was measured in
parallel with the expression of HIF-1a. Figure 6B shows that
both CAMPs were up-regulated in hypoxia. Finally, we
employed Transwell chemotactic assays to examine the hy-
pothesis that human PBSPCs respond to a low gradient of
SDF-1 in the presence of cathelicidin, which was similar to
our previous observations with HSCs [41]. Figure 6C shows
that LL37 enhanced the migration of PB-derived Lin - /
CD34 + cells toward low SDF-1 gradient that is ineffective in
inducing this migration by itself. Interestingly, neither C3a
alone as shown in the past [39] nor LL37 alone, as
FIG. 4. S1P receptors are expressed in naı̈ve BMSPCs, and
surface expression is reduced after exposure to S1P. Bar
graphs showing the expression of S1P receptor 1 and 3 on the
surface of BM-derived Lin - /CD34 + stem cells. The graphs
show a relatively higher expression of S1P receptors in the
BM stem cells that are reduced significantly after 2 h expo-
sure to S1P (250 nM) (*P < 0.05 as compared with controls).
BM, bone marrow.
FIG. 5. BMSPCs migrate toward
plasma from AMI patients in an S1P/
S1P receptor-dependent fashion. Bar
graphs showing the migration of line-
age-negative (Lin - )/CD34 + and
CXCR4-positive cells toward plasma
isolated from patients with AMI. As
shown, Lin - /CD34 + (A) and Lin - /
CXCR4 + (B) cells migrate toward
plasma isolated from AMI patients at
peak stem cell mobilization (*P < 0.05
as compared with controls). This mo-
bilization was blunted by CSP and the
use of selective S1P receptor 1 blocker
(W146) and S1P receptor 1 and 3 se-
lective blocker (VPC20139), where the
number of migrated BM stem cells was
not significantly different from vehicle.
CSP, charcoal stripped plasma; Lin - ,
lineage-negative cells.
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demonstrated here, was effective in inducing measurable
migration of PB-derived stem cells.
Discussion
AMI initiates multiple innate reparatory mechanisms, in-
cluding the activation of the CC that is responsible for the
release of bioactive lipids such as S1P and C1P from their
natural reservoirs in RBCs, platelets, and local endothelial
cells. In this study, we identify an important role of bioactive
lipids in the mobilization of BMSPCs into the PB after AMI.
We also demonstrate that AMI results in increased expression
of cathelicidins in the myocardium, resulting in a potential
role in priming circulating mobilized PBSPCs to physiological
SDF-1 levels and, hence, potentially improving their homing
to the ischemic myocardium. Taken together, these data
suggest that while the levels of SDF-1 in the myocardial tissue
may be influenced by the elevated levels of proteases, an in-
crease in CAMPs level enhances the responsiveness of non-
HSCs to SDF-1 gradient and may potentially be aiding in their
homing. These findings underscore the therapeutic potential
of strategies targeting the modulation of bioactive lipids, ca-
thelicidins, and their receptors in BMSPCs-based myocardial
regenerative studies.
It is well known that S1P is transported in PB mainly by
erythrocytes and is also associated with albumin and high-
density lipoprotein [58,59]. Our data show a 4–7-fold higher
content of S1P and C1P in erythrocytes compared with
plasma (Fig. 2). Erythrocytes can take up and release S1P,
and this buffering function likely explains the *· 25 higher
concentration of S1P in PB as compared with tissues. Innate
immune system activation after ischemic myocardial injury,
including the CC [44–48], may play an important role in the
release of S1P from blood cells such as activated platelets
[60–62], RBCs [58,63], and endothelial cells [28,64]. We
demonstrate for the first time that plasma levels of S1P and
C1P are significantly elevated after AMI (Fig. 1). The ele-
vated plasma levels of these bioactive lipids correlated with
the activation of the CC as evidenced by the elevated plasma
levels of C5b-9 (Supplementary Fig. S1). Furthermore, ex-
posure of erythrocytes to activated complement ex-vivo re-
sults in the release of bioactive lipids (Fig. 2), which could
explain the correlation between elevated plasma levels of S1P
in the setting of AMI and systemic complement activation.
The number of circulating hematopoietic stem and pro-
genitor cells increases in PB in response to systemic or local
inflammation, strenuous exercise and stress, tissue/organ
injury, and pharmacological agents. We and others have
demonstrated the mobilization of BMSPCs, including VSELs,
in PB shortly after acute myocardial injury [17–19,65–67].
The utilization of BM-derived populations enriched in VSELs
has been previously examined in animal and human studies
[68–70]. During these experiments, the regenerative capacity
of VSELs has been shown to improve the left ventricular
function after myocardial infarction. In the human study, the
benefit was observed mostly in patients with reduced left
ventricular function at baseline. Furthermore, in our initial
studies characterizing VSELs, we demonstrated the cardiac
differentiation capacity of BM-derived VSELs in vitro [10,71].
It is, however, important to mention that the surface
markers outlined in our study are not unique to any given
population of BM- or PB-derived stem cells. CD34 + and
FIG. 6. Cardiomyocytes increase the expression of cathelicidins after ischemic injury, and cathelicidins prime BMSPCs to
lower levels of SDF1. Bar graphs showing the increased mRNA expression of murine CRAMP and Defensin in murine cardiac
tissues subjected to 30 min hypoxia followed by 20 min reperfusion as compared with controls (A). The expression of CRAMP
and Defensin was also increased in cardiac fibroblasts subjected to 72 h of hypoxia in hypoxic chambers followed by
reperfusion as compared with 2 h of hypoxia and controls (B) (*P < 0.05 as compared with controls). (C) Demonstrates bar
graphs for the migration of lineage-negative (Lin - )/CD34 + -positive cells toward RPMI medium supplemented with 0.1%
fetal bovine serum alone (Vehicle), supplemented with SDF-1 (2 ng/mL) alone, LL37 (2.5 ng/mL) alone, or SDF-1 in addition
to LL37. As shown, Lin - /CD34 + cells migrate in significantly higher numbers toward SDF-1 in the presence of the priming
factor LL37 (*P < 0.05 as compared with controls). CRAMP, cathelicidins related antimicrobial protein; SDF-1, stromal derived
factor-1.
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CD133 + cells isolated from the PB have been shown to
differentiate into endothelial cells in vitro and home to is-
chemic limb in animal in vivo models [72–74]. EPCs are
mobilized in the setting of ischemic cardiac injury in corre-
lation with elevated levels of vascular endothelial growth
factor (VEGF) and express CD34, CD133, VEGF receptor 2,
and CXCR4 [17,18,75]. Thus, these non-HSCs represent
multiple overlapping subpopulations of stem/progenitor
cells such as EPCs, MSCs, and VSELs that are capable of
repopulating the injured heart and aid directly or indirectly
[76,77] in its regeneration.
Overall, the mobilization process has been postulated to
be directed by a decrease in SDF-1–CXCR4 and VLA-4–
VCAM-1 interactions in BM, reversal of the trans-endothelial
chemotactic gradient between the BM microenvironment
and plasma, activation of the coagulation cascade, and, fi-
nally, as recently postulated, activation of CC [27,28,40]. In-
terestingly, many of the earlier mentioned mechanisms and
cells are activated in the setting of AMI. The CC is activated
locally at sites of myocardial infarction with elevated levels
of C5b-9 both in the myocardium and plasma [48]. Recent
evidence suggests the role of C5b-9 and other members of the
CC in the mobilization and homing of BM stem cells
[28,38,39]. We demonstrate the activation of the CC in the
plasma after AMI. Our experiments also indicate that the
exposure of peripheral RBCs to activated complement results
in the release of bioactive lipids and, thus, can explain the
temporal correlation between the elevated levels of C5b-9
and bioactive lipids in the plasma of patients with AMI (Fig.
2). Taken together, these data support our hypotheses that
AMI activates the CC, which, in turn, activates the release of
bioactive lipids from RBCs.
Recently, S1P and C1P have been shown to be important
mediators in the signaling cascades involved in apoptosis/
survival, proliferation, stress responses, and cell trafficking
[78,79]. However, there are no data on the role of bioactive
lipids in the mobilization of BMSPCs in IHD. The data
shown here for the first time support an important role of
bioactive lipids in the mobilization of BMSPCs after MI. We
noted an elevated level of S1P and C1P in the plasma of MI
patients shortly after the onset of myocardial ischemia.
These levels showed a temporal correlation with the in-
creased numbers of circulating BMSPCs, suggesting a role
of bioactive lipids in this mobilization (Figs. 1 and 3). Fur-
thermore, plasma samples isolated from AMI patients at
peak BMSPCs mobilization were capable of chemoattract-
ing BMSPCs in migration assays, a phenomenon that was
blocked by delipidation of the plasma and selective S1Pr1
antagonists (Fig. 5).
On the other hand, assessing the role of C1P in this phe-
nomenon will be more challenging, as there are no known
receptor knockout or blocking agents for C1P. However, our
recent data from murine models demonstrate an increase in
C1P level in the myocardium after hypoxic injury and che-
motactic responsiveness of BM-derived EPCS, MSCs, and
VSELs to C1P gradient. These data support an involvement
of this bioactive lipid in regeneration of damaged tissues
[48]. Thus, our findings extend the role of bioactive lipids in
myocardial ischemia and mobilization of BMSPCs into PB.
However, we are aware that more work is needed to dem-
onstrate in in vivo models that damaged myocardium may
chemoattract circulating PB non-HSC in a bioactive lipid-
dependent manner. To address this question, our previous
data as well as the literature demonstrate a reduction in S1P
in the myocardium after AMI secondary to the up-regulation
of S1P lyase (data not shown). On the other, since C1P is
elevated in the myocardium after ischemia/reperfusion [48],
this suggests its potential role in homing of circulating
BMSPCs to the ischemic myocardium [26,80].
Studies mobilizing BM derived cells using granulocyte
colony stimulating factor or transplanting BM-derived cells
after ischemia-induced damage have faced limited en-
graftment and modest success [21,24,81–85]. Evidence from
animal studies demonstrate that BM cells mobilized in the
setting of AMI home to the myocardium but differentiate at
very low rates to cardiomyocytes [86]. Further evidence
suggests that paracrine factors released from BMSCs such
as cKit + cells recruit and stimulate resident cardiac stem
cells to proliferate, differentiate, and repair the myocardium
after ischemic injury [87]. Regardless of the mechanisms of
benefit, better engraftment of the transplanted cells is nee-
ded. After myocardial infarction, there is an elevation in the
MMPs at the site of infarction as early as few hours after the
acute event [56]. Elevated MMPs have been shown to de-
grade traditional chemokines such as SDF-1 [35] and
monocyte chemoattractant protein [36] among others, thus
lowering their chemoattractant activity. Recent evidence
suggests the role of cathelicidins in priming BM-derived
HSCs migration to lower levels of SDF-1 and their contri-
bution to HSCs homing to the BM after irradiation injury
[41]. We demonstrate that CAMPs are overexpressed after
myocardial ischemia in cardiac tissues as well as cardiac
fibroblasts. On the same note, the human CAMP-LL37
primes mobilized PBSPCs isolated from patients following
AMI to low, yet physiological, levels of SDF-1 (2 ng/mL)
(Fig. 6). This is in agreement with other studies which
showed that pre-incubating endothelial progenitor cells
with LL37 enhanced their homing and recruitment to areas
of hind limb ischemia and the process of neorevascular-
ization [88]. Taken together, these data support a potential
novel role for CAMPs in the homing of BMSPCs to the is-
chemic myocardium. These findings may have important
therapeutic implications in planning future BMSPCs-based
myocardial regenerative studies. Since the members of the
innate immune system have been successfully employed to
enhance homing of HSCs into BM [37,89,90], we are cur-
rently examining similar pathways in enhancing the hom-
ing of transplanted BM-derived stem cells into the ischemic
myocardium after AMI in animal models.
In conclusion, this study highlights the potential role of
bioactive lipids and cathelicidin in the mobilization and
homing of BM derived cells to the ischemic myocardium
with their potential role in cardiomyocyte chimerism. Mul-
tiple new therapies that modulate the plasma levels of S1P or
S1Pr expression are approved by the FDA and can be uti-
lized in improving the mobilization of BM-derived stem cells
in myocardial ischemia. Similarly, priming of BM-derived
cells with LL37 or a product of the activated CC such as C3a
can be used to improve their homing to the ischemic myo-
cardium and, thus, overcome a major hurdle in stem cell
regenerative myocardial therapies. We are currently exam-
ining both strategies in our laboratory to improve the mo-
bilization and homing of BMSPCs to the ischemic
myocardium.
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